In a nutshell This study investigated the side effect profiles of different PD-1/PD-L1 inhibitor-based combination therapies. The data showed that PD-1/PD-L1 inhibitors in combination with chemotherapy were associated with a higher risk of treatment-related side effects than with targeted therapy or immunotherapy combinations. Some background...
Read More
In a nutshell This study investigated the side effect profiles of different PD-1/PD-L1 inhibitor-based combination therapies. The data showed that PD-1/PD-L1 inhibitors in combination with chemotherapy were associated with a higher risk of treatment-related side effects than with targeted therapy or immunotherapy combinations. Some background...
Read More
In a nutshell This study aims to investigate the long-term effectiveness and safety of the rituximab biosimilar CT-P10 (Truxima) in combination with cyclophosphamide (Cytoxan), vincristine (Oncovin), and prednisone (Deltasone) (CVP) compared with rituximab (Rituxan) for the treatment of advanced-stage follicular lymphoma (FL). The...
Read More
In a nutshell The study evaluated the association of interleukin-2 (IL2) receptor (R) levels in the blood (a protein present on immune cells) in selecting a treatment for advanced-stage follicular lymphoma with a low tumor burden (FL-LTB). The study showed that patients with high IL-2R levels had better survival when treated with...
Read More
In a nutshell This study presents 5-year results for the targeted antibody therapy brentuximab vedotin (BV; Adcetris) for patients with advanced Hodgkin lymphoma (HL) who had not been previously treated. It found that BV with chemotherapy led to less recurrence of HL compared to chemotherapy alone. Some background The outcomes for patients with the...
Read More
In a nutshell This study reported the long-term effectiveness and safety outcomes of changing treatment intensity after a PET scan for patients with advanced-stage Hodgkin lymphoma (HL). The data showed that reducing treatment intensity after a negative PET scan and continuing standard-dose treatment after a positive PET scan was safe and effective over...
Read More
In a nutshell The study evaluated the impact of consolidation radiotherapy (cRT) on patients with advanced Hodgkin lymphoma (HL) who had large nodal mass (LNM) and currently in complete metabolic response (CMR) after receiving ABVD chemotherapy. The authors found that cRT could be safely avoided in such patients. Some background CMR defines...
Read More
In a nutshell This study looked at the effect of a gentler stem cell transplant (SCT) from a partially matched donor for patients with advanced lymphoma. It found that haploidentical SCT is an effective treatment option for these patients. Some background Lymphomas are a group of cancers of white blood cells within the lymph nodes. Common types...
Read More
In a nutshell This study looked at the effectiveness of rituxumab (Rituxan) with lenalidomide (Revlimid) for untreated follicular lymphoma (FL). It found that this treatment was more effective than rituxumab with chemotherapy. They also found that blood tests of trace FL can predict outcomes. Some background Follicular lymphoma (FL) is a slow-growing...
Read More
In a nutshell This study compared the effectiveness and safety of ABVD and BEACOPP chemotherapy for patients with advanced Hodgkin lymphoma (HL). The authors found that while BEACOPP was more effective in the short term, ABVD was as effective in the long term and safer for patients. Some background Chemotherapy is the standard initial treatment...
Read More
In a nutshell This study examined if international prognostic scores (IPS) could help predict treatment outcomes for patients with advanced Hodgkin's lymphoma (HL). The authors found that the IPS system is losing its predictability as treatment strategies improve for these patients. Some background Patients with HL need to be treated...
Read More
In a nutshell This article reviewed different treatment approaches for patients with advanced Hodgkin's lymphoma (HL). Some background HL is a type of blood cancer of the lymphatic system. HL can be classified in different ways. In limited HL, cancer is found in one or two sites in the lymphatic system. In advanced HL, cancer is found on...
Read More
